Takeaways
#- Thwaites looked for individual biotech strength even while the broader XBI chart remained untidy.
- She used roughly $11.50 in Adaptive and $7.50 in Amylyx as conditions for her bullish chart views.
- She acknowledged that overnight biotech news could overwhelm a nearby intended exit and therefore considered position size.
- Parets, Strazza and Rosebee distinguished attractive themes from the question of which asset offered the best entry and return potential.
Mary Thwaites did not need the entire biotech group to look healthy before finding individual stocks worth watching. On the August 13, 2025 Morning Show, she described XBI as messy while identifying several companies with clearer price levels underneath it.
That distinction fit the morning’s broader discussion. Spencer Israel, JC Parets and Steve Strazza were looking across a strong market in which leadership was uneven. Some assets had already advanced sharply; others were still working through bases. The choice of security and entry mattered even when the speakers agreed on the general direction.
Ethereum and Solana posed different allocation questions
Parets and Strazza opened with their disagreement over Ethereum and Solana. Parets preferred his Ethereum exposure. Strazza was giving Solana the benefit of the doubt because of the rotation he had seen in earlier crypto cycles.
They also separated relative strength from absolute returns. Ethereum could outperform Solana while both declined. Conversely, Parets expected a strong Solana phase to accompany a favorable environment for his Ethereum holdings, even if he did not own the strongest asset in that stretch.
Thwaites owned both. She had recently added to Solana after it recovered above VWAP anchored to an earlier high. That level gave her a defined chart reference for the added exposure, while her upside interest extended toward the former highs and potentially beyond.
She also brought a shorter-term BitMine Immersion setup. The stock had formed a small consolidation, and she was watching for a move above roughly $68 before entering. Her interest was the chart and its active participation; she was not presenting a completed purchase.
Two biotech levels, with an overnight caveat
Adaptive Biotechnologies was one of Thwaites’ preferred examples. The stock had spent months meeting resistance around $11.50 to $12. An anchored VWAP converged near the lower end of that area, and price was now trading above it. She liked the long side while it held above approximately $11.50.
Amylyx Pharmaceuticals offered a similar change in the role of a price level. Thwaites marked $7.50 as a zone the stock had tested, fallen away from and then recovered. Remaining above it supported her bullish view. A move back below it would mean the setup was not ready.
She was explicit about the limit of those chart references. A disappointing trial result or other overnight news could produce a sharp gap, so position size mattered even when the intended exit looked close on a chart. She was not claiming expertise in each company’s drug pipeline.
Her interest in the group also reflected the possibility of lower interest rates. In response to Rosebee, she said anticipated cuts had helped lead her toward rate-sensitive businesses, including biotech. But she acknowledged that positioning for them preceded the actual policy decision. She also said she did not own every stock she had brought to the discussion.
Tesla’s chart did not settle the valuation argument
Earlier, Rosebee had made the case for autonomous transport. Tesla’s ability to hold around $300 despite negative news mattered to him, and he saw a much larger opportunity in changing how people obtained transportation.
Strazza liked the chart but questioned the potential return from a company already worth around $1.1 trillion. A tenfold increase would imply an enormous future market value. He preferred to consider whether smaller companies such as EHang or XPeng offered more upside from their starting sizes.
Rosebee placed greater weight on the operating progress and practical reach of the service he wanted to see. The disagreement was over how to participate in the theme, rather than whether the technology was interesting.
Strazza also discussed Pony AI’s chart, noting that he had traded it earlier in the year but did not currently hold it. His interest remained a potential setup. As with Thwaites’ watchlist, an appealing chart and an existing position were not interchangeable.
Questions and answers
#Questions answered in the original 2025-08-13 episode.
Why was Thwaites watching Adaptive Biotechnologies?
Prior resistance around $11.50 to $12 overlapped an anchored VWAP near $11.50. Price had recovered above the area, and she liked the long side while it held above roughly $11.50.
What would change her Amylyx setup?
A return below $7.50 would invalidate the bullish setup she described. She also emphasized that overnight company news could cause a large gap, making position size part of her decision.
Why did Strazza question Tesla despite liking its chart?
He considered its approximately $1.1 trillion starting market value a constraint on the size of a potential future return. He thought smaller companies in related transport themes might offer more upside, while Rosebee emphasized operating progress and the scale of the service opportunity.
Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .